LZAGY News and Press, Lonza Group AG ADR From 03/06/22

Seres misses on earnings and revenue, although revenue was up 344% to $144.92 million. Net loss of $50.00 million in Q4 compared with $18.3 million in Q4 2020, due significantly to preparing for launch of SER-109. Key publication on SER-109 C.difficile results and signs remain goo...

Lonza is a Swiss company in the pharmaceutical ingredients sector. The stock has historically always been expensive and isn't cheap now. Between now and 2024, the EBITDA will increase by 50%, so the company is aiming for an impressive growth trajectory. This still doesn't make...

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate PR Newswire Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Gua...

A group of analysts from KeyBank Capital Markets has named several life sciences companies that could benefit from renewed demand for PCR tests and COVID-19 vaccines after the emergence of the newly detected Omicron variant. While noting that it is too early to identify the impact of the vari...

Lonza Group (OTC: LZAGY) isn't in the limelight very much. However, Lonza is a relatively large company that is a key player in making COVID-19 vaccines. In this Motley Fool Live video recorded on Nov. 3, 2021 , Motley Fool contributors Keith Speights and Brian Orelli discus...

Lonza enjoys an excellent brand reputation in the pharmaceutical industry. This leads to a premium valuation, and even after selling a lower-margin division, the valuation is quite high. I'm on the sidelines but I'm interested in the company's growth plans and its mid-30% EBITDA m...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Total return for Harding Loevner International Equity Fund net of fees was 5.43% vs. MSCI All Country World ex-US ...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

Lonza Group AG (LZAGY) Q2 2021 Earnings Conference Call July 23, 2021, 08:00 ET Company Participants Pierre-Alain Ruffieux - CEO Rodolfo Savitzky - CFO Conference Call Participants Daniel Jelovcan - Mirabaud Matthew Weston - Crédit Suisse Patrick Wood - Bank of America Merrill Lynch Char...

The following slide deck was published by Lonza Group Ltd in conjunction with their 2021 Q2 earnings call. For further details see: Lonza Group Ltd 2021 Q2 - Results - Earnings Call Presentation